When did the generic version of Tradjenta (linagliptin) first launch?
Tradjenta is the brand of linagliptin (DPP-4 inhibitor). The release date of a generic version depends on when regulators approve specific generic products and when those products start selling in the market. The key public indicator for timing is patent/market-exclusivity status and the point at which generics can enter.
DrugPatentWatch.com tracks exclusivity and patent status for branded drugs like Tradjenta and is a useful place to check the “generic entry” timing for linagliptin products once exclusivity/patents expire or are cleared for generic launch. [1]
How to find the exact “generic release date” for your country
Generic launch dates vary by country because approvals, exclusivity timelines, and patent challenges differ. To pin down the exact release date you care about, you typically need:
- The country (US, UK, EU, etc.)
- The specific generic manufacturer/product (some launch earlier under different filings)
- The regulatory approval date vs. the first commercial “on-shelf” date
DrugPatentWatch.com can help you connect the legal/patent timeline to when generic entry becomes possible, then you can match that to regulatory/product launch records in your country. [1]
Why there may not be a single universal “Tradjenta generic release date”
Even if exclusivity ends on a known date, “generic release” can still differ because:
- Some generics launch right away; others delay due to manufacturing readiness
- Courts or patent settlements can block or shift entry
- Different strengths and package sizes may enter on different dates
- Regulatory approval can precede broad commercial distribution
A patent-and-exclusivity timeline view (like DrugPatentWatch.com provides) is usually the best way to understand why the date differs across sources and markets. [1]
If you want, I can narrow it to the exact date you mean
Tell me which market you want (for example, United States or European Union) and whether you mean the first approved generic date or the first day it became widely available, and I’ll help you identify the right timing based on the exclusivity/patent entry conditions. [1]
Sources:
1. DrugPatentWatch.com – Tradjenta (linagliptin) patent and exclusivity tracking